Acquired Assets Nexgen Pharma’s formulation development and drug product contract manufacturing business was acquired by LGM Pharma, indicating a strategic exit or transition; potential cross-sell opportunities may exist with LGM Pharma's existing client base and expanded service offerings.

Focused Specialties Specialty pharmaceutical focus with capabilities in Rx, OTC and custom dietary supplement formulations suggests opportunities to engage for contract development, clinical formulation optimization, and scalable manufacturing for niche product lines.

Quality & Experience Over 80 years of manufacturing experience and a stated rigorous commitment to quality position Nexgen as a trusted partner for high-compliance product development and cGMP manufacturing, appealing to brands seeking reliability and robust quality systems.

Mid-size Capacity Employee range of 51-200 indicates mid-sized operations with potential agility and personal account management; target campaigns can emphasize dedicated project teams, flexible scheduling, and faster turnaround times for mid-market clients.

Growth Signals Revenue in the established range of $100M-$250M combined with the acquisition by LGM Pharma suggests potential for integration-driven expansion, enabling sales discussions around joint ventures, co-development, or expanded manufacturing capacity.